This HTML5 document contains 109 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00696/identifier/wikipedia/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00696/identifier/pharmgkb/
n5http://linked.opendata.cz/resource/drugbank/mixture/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00696/identifier/kegg-compound/
n17http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB00696/identifier/pubchem-compound/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00696/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB00696/identifier/drugbank/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/medicinal-product/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00696/identifier/national-drug-code-directory/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n18http://www.drugs.com/cdi/
n19http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n13http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00696/identifier/chemspider/
n25http://linked.opendata.cz/resource/atc/
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00696
rdf:type
n3:Drug
n3:description
A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. [PubChem]
n3:dosage
n23:271B47E3-363D-11E5-9242-09173F13E4C5 n23:271B47E4-363D-11E5-9242-09173F13E4C5 n23:271B47E5-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ: Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000 Jan;123 ( Pt 1):9-18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10611116 # Schardl CL, Panaccione DG, Tudzynski P: Ergot alkaloids--biology and molecular biology. Alkaloids Chem Biol. 2006;63:45-86. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17133714
n3:group
approved
n3:halfLife
2 hours
n3:indication
For use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia".
n3:manufacturer
n6:271B47DC-363D-11E5-9242-09173F13E4C5 n6:271B47DD-363D-11E5-9242-09173F13E4C5 n6:271B47DA-363D-11E5-9242-09173F13E4C5 n6:271B47DB-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00696 n26:DB00696
dcterms:title
Ergotamine
adms:identifier
n8:DB00696 n9:7930 n10:8223 n11:C07544 n14:0089-0762-21 n15:46507632 n20:PA164747651 n21:Ergotamine
n3:mechanismOfAction
Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT<sub>1D</sub> receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT<sub>1D</sub> receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.
n3:packager
n6:271B47D8-363D-11E5-9242-09173F13E4C5 n6:271B47D9-363D-11E5-9242-09173F13E4C5 n6:271B47D6-363D-11E5-9242-09173F13E4C5 n6:271B47D7-363D-11E5-9242-09173F13E4C5 n6:271B47D4-363D-11E5-9242-09173F13E4C5 n6:271B47D5-363D-11E5-9242-09173F13E4C5 n6:271B47D2-363D-11E5-9242-09173F13E4C5 n6:271B47D3-363D-11E5-9242-09173F13E4C5 n6:271B47D0-363D-11E5-9242-09173F13E4C5 n6:271B47D1-363D-11E5-9242-09173F13E4C5 n6:271B47CF-363D-11E5-9242-09173F13E4C5 n6:271B47CD-363D-11E5-9242-09173F13E4C5 n6:271B47CE-363D-11E5-9242-09173F13E4C5
n3:synonym
Ergotaminum Ergotamin (5'alpha)-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione Gynergen Ergotamine Ergotamina 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione
n3:toxicity
Signs of overexposure include irritation, nausea, vomiting, headache, diarrhea, thirst, coldness of skin, pruritus, weak pulse, numbness, tingling of extremities, and confusion.
n3:foodInteraction
Caffeine increases absorption. Take without regard to meals.
n3:mixture
n5:271B47CC-363D-11E5-9242-09173F13E4C5 n5:271B47CA-363D-11E5-9242-09173F13E4C5 n5:271B47CB-363D-11E5-9242-09173F13E4C5 n5:271B47BC-363D-11E5-9242-09173F13E4C5 n5:271B47BD-363D-11E5-9242-09173F13E4C5 n5:271B47BA-363D-11E5-9242-09173F13E4C5 n5:271B47BB-363D-11E5-9242-09173F13E4C5 n5:271B47C0-363D-11E5-9242-09173F13E4C5 n5:271B47C1-363D-11E5-9242-09173F13E4C5 n5:271B47BE-363D-11E5-9242-09173F13E4C5 n5:271B47BF-363D-11E5-9242-09173F13E4C5 n5:271B47C4-363D-11E5-9242-09173F13E4C5 n5:271B47C5-363D-11E5-9242-09173F13E4C5 n5:271B47C2-363D-11E5-9242-09173F13E4C5 n5:271B47C3-363D-11E5-9242-09173F13E4C5 n5:271B47C8-363D-11E5-9242-09173F13E4C5 n5:271B47C9-363D-11E5-9242-09173F13E4C5 n5:271B47C6-363D-11E5-9242-09173F13E4C5 n5:271B47C7-363D-11E5-9242-09173F13E4C5
n3:salt
foaf:page
n13:caf1060.shtml n18:ergotamine.html n19:ergotamine.htm
n3:IUPAC-Name
n4:271B47EA-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B47F0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B47EF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B47EC-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B47ED-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B47EE-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B47E8-363D-11E5-9242-09173F13E4C5 n4:271B4800-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4802-363D-11E5-9242-09173F13E4C5 n4:271B47E6-363D-11E5-9242-09173F13E4C5 n4:271B47E9-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B47E7-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n25:N02CA02
n3:H-Bond-Acceptor-Count
n4:271B47F6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B47F7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B47F1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B47F2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B47F4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B47F3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B47F5-363D-11E5-9242-09173F13E4C5
n3:absorption
The bioavailability of sublingually administered ergotamine has not been determined.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
113-15-5
n3:containedIn
n22:271B47E2-363D-11E5-9242-09173F13E4C5 n22:271B47E1-363D-11E5-9242-09173F13E4C5 n22:271B47DF-363D-11E5-9242-09173F13E4C5 n22:271B47E0-363D-11E5-9242-09173F13E4C5 n22:271B47DE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B47FC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B47FE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B47FF-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4801-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B47FB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B47FA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B47FD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B47EB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B47F8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B47F9-363D-11E5-9242-09173F13E4C5